Potential probiotic of Lactobacillus johnsonii LT171 for chicken nutrition

The objective of this research was to investigate the potential probiotic of Lactobacillus johnsonii LT171. It had aggregation (60 min) and antibacterial effects against Salmonella Enteritidis, Salmonella Typhimurium and Escherichia coli O78:K80. It showed amylase and protease activity and high clear zone in culture medium containing calcium phytate; cell surface hydrophobicity, 85.21 ± 7.27%; resistance to acidic condition (pH 3 for 90 min) and bile salts (in culture medium containing 0.075% ox gall). Also it had resistance to nalidixic acid and neomycine. This research showed appropriate probiotic properties of L. johnsonii LT171 for chicken nutrition. Hence this strain can complement the characteristics of other strains in multistrain probiotics because of its high clear zone in culture medium containing calcium phytate

Kinetic model for polyhydroxybutyrate (PHB) production by Hydrogenophaga pseudoflava and verification of growth conditions

A kinetic model that describes microbial growth, biopolymer production and substrate consumption is used to predict the performance of batch fermentation of Hydrogenophaga pseudoflava. H. pseudoflava DSMZ 1034 is useful in synthesizing polyhydroxyalkanoates (PHAs).The experimental data was also fitted with the logistic equation that can provide adequate description for PHA synthesized by H. pseudoflava. The Lineweaver-Burk plot defined biokinetic coefficients which were described by a simplified Monod’s rate model. The specific growth rates, max and the Monod constants, Ks, for various substrates such as glucose, fructose were 0.36, 0.24, h-1 and 106, 80 g/l, respectively. A good agreement was found between the experimental and the predicted values, which indicated that the model with differential equations would describe fermentation process for the PHA formation

ATPS as an Efficient Method for Separation of Bionanoparticles: Investigation and Optimization of Partition Behavior of pDNA

In this paper, the efficiency of an aqueous two-phase system (ATPS) for purification of nanometer-sized bioparticles, plasmid DNA (pDNA), was studied. Polymer-salt ATPS consisting of polyethylenglycol (PEG)-K2HPO4 was used for the purification of 7 kb and 14 kb plasmid vectors. PEG-300 and PEG-1450 were applied to investigate the influence of different molecular mass of PEGon partitioning behavior of pDNA. The Taguchi design of experiments has been applied in order to optimize the significant system characteristics including PEG/salt ratio, temperature, lysate mass fraction and size of plasmid for pDNA separation by using ATPS. The results indicated that PEG/salt ratio has a considerable contribution on pDNA recovery both in the presence of PEG-300 and PEG-1450. It is also obtained that the size of pDNA in the range of 7 kb to 14 kb is not a significant factor on its partitioning. Furthermore, pDNA is easily partitioned to polymer-rich top phase in PEG300/salt system; and in salt-rich bottom phase in PEG1450/salt system. Under optimum conditions, pDNA was extracted in top phase of PEG-300/K2HPO4 with mass percent of 26 : 17 at 25 °C with a recovery percent of 85

Cloning and Expression of Immunogenic Regions of EMA-1 Gene of Theileria equi From Infected Horses

Diversity among the pathogenic strains of Theileria equi (T. equi), a major agent of equine piroplasmosis, can affect the appropriate detection of parasite and host immunization. Production of recombinant surface proteins from an infected horse in natural endemic area provides a reliable tool for immunodiagnosis of parasite. Regarding this, the present study was targeted toward the cloning, expression, and purification of the immunogenic regions of equine merozoite antigen 1 (EMA-1 gene), as one of the most important immunodominant surface proteins in T. equi, from naturally infected horses in Iran. The immunogenic region of EMA-1 gene was amplified using the blood of infected horses. EMA-1 gene was cloned into pET26b vector. Then, recombinant plasmids (pET 26b-EMA-1) were transformed into competent E. coli BL21 (DE3) cells. Cloning was confirmed by polymerase chain reaction (PCR), restriction enzyme assays, and DNA sequence analysis. The recombinant protein was expressed using isopropyl β-D-1-thiogalactopyranoside as an inducer, purified using nickle-nitrilotriacetic acid column, and then confirmed by 10% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and dot blot analysis utilizing Anti-His Tag antibody. Furthermore, the immunoreactivity of recombinant protein against the serum of the infected horses was evaluated using dot blot analysis. The PCR product analysis showed a 750-bp band belonging to immunogenic regions of EMA-1 gene. Sequence analysis revealed that cloned EMA-1 and protein had 94% and 97% homology to EMA-1 sequences submitted to GenBank from different countries, respectively. Restriction enzyme and sequence analyses confirmed the subcloning and correction of the orientation of inserted gene. The SDS-PAGE analysis confirmed the expression of EMA-1 protein with a 28-kDa band. The results of the dot blot analysis revealed that the horse serum containing antibody against T. equi could react with the purified recombinant protein. Purified EMA-1 protein can be used as a reliable tool for the future development of diagnostic tests or vaccines

Purtscher-like retinopathy following valsalva maneuver effect: case report

<p>Abstract</p> <p>Introduction</p> <p>Purtscher's retinopathy is a rare condition that is noted in cases related to various types of trauma. The characteristic finding in the fundus is the presence of multiple Purtscher flecken. Purtscher-like retinopathy has a similar presentation in the fundus, but without an association with trauma.</p> <p>Case presentation</p> <p>A 43-year old Malay man presented with a sudden onset of central foggy vision in the left eye after holding his breath for two minutes while catching a falling object. It was not associated with floaters, flashes of light, or head trauma. His vision in the right eye was 6/6, and in his left eye it was finger counting. He had bilateral temporal sub-conjunctival hemorrhages. An examination of his left fundus revealed multiple white cotton wool spots and dot-blot retinal hemorrhages with diffuse retinal edema at the posterior pole. His right fundus was noted to have only mild temporal peri-papillary edema associated with a few dot-blot hemorrhages. Fundus fluorescein angiography showed good arterial perfusion and no evidence of leaking or neo-vascularization. A diagnosis of Purtscher-like retinopathy was made, and the patient was treated with indomethacin tablets for six weeks. At his six-week follow-up examination, his left eye visual acuity had improved to 6/12. His bilateral sub-conjunctival hemorrhage had resolved. His left fundus showed residual multiple cotton wool spots and reduced retinal edema.</p> <p>Conclusions</p> <p>Treatment with non-steroidal anti-inflammatory drugs seems to be effective in reducing edema in patients with Purtscher-like retinopathy.</p

Changes in the Circadian Rhythm in Patients with Primary Glaucoma

Purpose The current study was undertaken to investigate whether glaucoma affects the sleep quality and whether there is any difference between patients with primary glaucoma (primary open angle glaucoma, POAG and primary angle-closure glaucoma, PACG) and healthy subjects, using a validated self-rated questionnaire, the Pittsburgh Sleep Quality Index (PSQI). Methods The sleep quality of patients with POAG and PACG was tested against normal controls. Subjects were divided into three sub-groups according to age. Differences in the frequency of sleep disturbances (PSQI score >7) were assessed. The differences of sleep quality within the three groups and within the POAG group depending on the patients’ intraocular pressure (IOP) and impairment of visual field (VF) were also studied. Results 92 POAG patients, 48 PACG patients and 199 controls were included. Sleep quality declined with age in control and POAG group (tendency chi-square, P0.05). No significant differences were found in POAG group between patients with a highest IOP in daytime and at nighttime (χ2-test, P>0.05). Conclusions The prevalence of sleep disorders was higher in patients with POAG and PACG than in controls. PACG patients seemed to have a more serious problem of sleep disorders than POAG patients between 61 to 80 years old. No correlation was found between the prevalence of sleep disorders and impairment of VF or the time when POAG patients showed a highest IOP

Circadian-Related Sleep Disorders and Sleep Medication Use in the New Zealand Blind Population: An Observational Prevalence Survey

STUDY OBJECTIVES: To determine the prevalence of self-reported circadian-related sleep disorders, sleep medication and melatonin use in the New Zealand blind population. DESIGN: A telephone survey incorporating 62 questions on sleep habits and medication together with validated questionnaires on sleep quality, chronotype and seasonality. PARTICIPANTS: PARTICIPANTS WERE GROUPED INTO: (i) 157 with reduced conscious perception of light (RLP); (ii) 156 visually impaired with no reduction in light perception (LP) matched for age, sex and socioeconomic status, and (iii) 156 matched fully-sighted controls (FS). SLEEP HABITS AND DISTURBANCES: The incidence of sleep disorders, daytime somnolence, insomnia and sleep timing problems was significantly higher in RLP and LP compared to the FS controls (p<0.001). The RLP group had the highest incidence (55%) of sleep timing problems, and 26% showed drifting sleep patterns (vs. 4% FS). Odds ratios for unconventional sleep timing were 2.41 (RLP) and 1.63 (LP) compared to FS controls. For drifting sleep patterns, they were 7.3 (RLP) and 6.0 (LP). MEDICATION USE: Zopiclone was the most frequently prescribed sleep medication. Melatonin was used by only 4% in the RLP group and 2% in the LP group. CONCLUSIONS: Extrapolations from the current study suggest that 3,000 blind and visually impaired New Zealanders may suffer from circadian-related sleep problems, and that of these, fewer than 15% have been prescribed melatonin. This may represent a therapeutic gap in the treatment of circadian-related sleep disorders in New Zealand, findings that may generalize to other countries